Stryker: Operational Excellence Meets Demographics
Stryker dominates the market for computer-assisted surgery with its Mako robotics, securing long-term market shares and highly profitable, recurring revenues.
Reading Time: 2 minutes
Stryker's stock (i) serves as an anchor of stability. Anyone looking to build a portfolio for eternity seeks companies that not only grow but also have a business model that is almost immune to economic cycles. The figures presented on January 29, 2026, for the fourth quarter and the full year 2025 impressively highlighted why the medical technology giant meets these criteria. With a revenue jump of over 11% to $7.2 billion in the final quarter alone, Stryker demonstrates a momentum rarely seen in a company of this size. Particularly impressive...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
